Astrana Health (NASDAQ:ASTH) Price Target Cut to $46.00 by Analysts at Truist Financial

Astrana Health (NASDAQ:ASTH) had its target price lowered by Truist Financial from $50.00 to $46.00 in a research note released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the company. Macquarie upgraded Astrana Health to a “hold” rating in a research note on Monday, December 16th. Bank of America dropped their target price on Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Stifel Nicolaus cut their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Finally, Robert W. Baird lowered their price objective on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Astrana Health presently has a consensus rating of “Moderate Buy” and an average target price of $56.17.

Astrana Health Stock Performance

ASTH stock opened at $32.03 on Tuesday. The stock’s 50 day simple moving average is $33.97 and its 200 day simple moving average is $42.83. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health has a 12-month low of $23.12 and a 12-month high of $63.20. The stock has a market capitalization of $1.80 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). The business had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. As a group, research analysts forecast that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Institutional Trading of Astrana Health

Several institutional investors and hedge funds have recently modified their holdings of ASTH. Vanguard Group Inc. boosted its holdings in Astrana Health by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 4,685,959 shares of the company’s stock worth $147,748,000 after buying an additional 20,757 shares during the period. State Street Corp purchased a new position in shares of Astrana Health in the third quarter valued at about $91,966,000. Dimensional Fund Advisors LP boosted its stake in shares of Astrana Health by 10.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,045,540 shares of the company’s stock worth $32,968,000 after acquiring an additional 101,192 shares during the period. Geode Capital Management LLC purchased a new stake in shares of Astrana Health during the third quarter worth about $58,995,000. Finally, 325 Capital LLC raised its stake in Astrana Health by 30.3% during the 4th quarter. 325 Capital LLC now owns 886,916 shares of the company’s stock valued at $27,964,000 after purchasing an additional 206,009 shares during the period. 52.77% of the stock is currently owned by institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.